Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2023-10-13 Major Shareholding Noti…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is titled 'TR-1: Standard form for notification of major holdings' and is issued via 'RNS Number : 0718Q' by Dechra Pharmaceuticals PLC on October 13, 2023. This form is used to report changes in significant share ownership (crossing thresholds) by institutional investors (Societe Generale in this case). This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is a regulatory filing, MRQ is a more specific category than the general RNS fallback.
2023-10-13 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is identified by the header 'RNS Number : 0715Q' and explicitly mentions 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details a 'TR-1: Standard form for notification of major holdings' by Societe Generale, indicating a change in significant share ownership (crossing the 5% threshold, moving from 8.05% to 6.74%). This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content type is MRQ, which takes precedence over the general RNS fallback.
2023-10-13 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 99% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used to disclose personal share transactions or holdings by parties involved in a takeover bid. This activity falls under insider trading/director's dealing disclosures, specifically related to takeover activity. Among the provided codes, "Director's Dealing (Code: DIRS)" is the closest fit for reporting personal transactions by insiders/major holders, even though this specific form (Form 8.3) is highly specialized for takeover situations. Since there is no specific code for 'Takeover Disclosure Form 8.3', DIRS is the most appropriate category for reporting personal dealings by influential persons. The document details interests and derivative transactions, confirming it is a disclosure of dealings.
2023-10-12 English
Preliminary results - year ended 30 June 2023
Earnings Release Classification · 100% confidence The document explicitly states it contains 'audited preliminary results for the year ended 30 June 2023' and provides detailed financial summaries, including revenue, operating profit, and EPS comparisons between 2023 and 2022. The title is 'Preliminary Results Announcement'. This content strongly indicates a comprehensive report covering a full fiscal year's performance, which aligns with the definition of an Annual Report (10-K). However, the document is issued on October 12, 2023, and refers to results for the year ended June 30, 2023. In many jurisdictions (especially outside the US SEC filing system), a 'Preliminary Results Announcement' that details the full year's audited figures is often the primary annual disclosure, which maps best to the '10-K' category for comprehensive annual financial reporting, or potentially 'ER' (Earnings Release) if it were only quarterly. Given the depth, the mention of 'audited preliminary results', and the full-year scope, it is a primary annual financial disclosure. Since the document is very long (169k chars) and contains the full results, it is the report itself, not just an announcement of the report (RPA). While it is a preliminary announcement, the content is the full annual result disclosure, making 10-K the most appropriate fit for comprehensive annual financial reporting, although 'ER' (Earnings Release) is also plausible for a preliminary announcement. Given the full-year scope and detailed tables, 10-K is chosen over ER, which is typically for quarterly highlights. If a specific 'Annual Report' code existed for non-US filings, it would be better, but 10-K serves as the best proxy for a comprehensive annual filing. FY 2023
2023-10-12 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'FORM 8.3 - Dechra Pharmaceuticals plc' and contains the header 'PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE' under 'Rule 8.3 of the Takeover Code (the “Code”)'. This form is used by parties involved in a takeover bid to disclose their interests and dealings in the relevant securities, which is a specific type of insider/director dealing disclosure related to M&A activity, but more precisely, it is a mandatory disclosure under the UK Takeover Code regarding shareholdings during an offer period. While it involves director/insider activity, the context is strictly related to a takeover bid (implied by the reference to 'offeror/offeree' and 'Takeover Code'). However, the closest general category that covers personal share transactions by executives/insiders is 'Director's Dealing' (DIRS). Given the specific nature of Rule 8.3 disclosures during a takeover, it is a specialized form of insider dealing disclosure. Since there is no specific code for 'Takeover Code Disclosure', DIRS is the most appropriate fit among the provided options, as it deals with personal share transactions by interested parties. It is not a general M&A announcement (TAR), but a disclosure of holdings/dealings by a major shareholder during an ongoing situation.
2023-10-11 English
Form 8.3 - Dechra Pharmaceuticals plc
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled "FORM 8.3 - PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE" and references "Rule 8.3 of the Takeover Code (the “Code”)". This form is used to disclose dealings and positions related to a takeover offer. While it involves director/insider-like activity (Director's Dealing - DIRS), the specific context of a takeover code disclosure (Rule 8.3) is highly specific. This type of filing, which reports insider/significant shareholder activity during a takeover period, is not explicitly covered by DIRS (which usually refers to routine insider trading reports like Form 4 or DTR3). Since it relates to a takeover/merger situation (Dechra Pharmaceuticals plc is the offeree), it is most closely related to M&A Activity (TAR). However, the core function is reporting a change in holding/dealing by a significant party under specific regulatory rules (Takeover Code). Given the options, this disclosure of a significant shareholder's position and dealings during a potential takeover scenario aligns best with the scope of M&A Activity (TAR), as it is a direct consequence of the takeover process. If TAR were not available, it might fall under Regulatory Filings (RNS), but TAR is a better fit for takeover-related disclosures.
2023-10-10 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.